Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical decision-making and treatment of myelodysplastic syndromes
Eva S. Hellström-Lindberg, Nicolaus Kröger
Blood (2023) Vol. 142, Iss. 26, pp. 2268-2281
Closed Access | Times Cited: 11

Showing 11 citing articles:

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms
Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1563-1563
Open Access | Times Cited: 6
Realgar induces apoptosis by inhibiting glycolysis via regulating STAT3 in myelodysplastic syndrome
Tingting Xue, Yuchen Tao, Zong Wu, et al.
Journal of Ethnopharmacology (2025) Vol. 341, pp. 119339-119339
Closed Access
Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome
Theodoros Nikolopoulos, Eleftherios Bochalis, Theodora Chatzilygeroudi, et al.
Molecular Medicine (2025) Vol. 31, Iss. 1
Open Access
Selecting optimal therapy for higher-risk myelodysplastic syndromes: present and future projections
Farzad Teymouri, Constantin A Dasanu
Expert Opinion on Pharmacotherapy (2025)
Open Access
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Athanasios Tasis, Theodoros Spyropoulos, Ioannis Mitroulis
Cancers (2025) Vol. 17, Iss. 5, pp. 749-749
Open Access
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review
Nico Gagelmann, Nicolaus Kröger
American Journal of Hematology (2025)
Open Access
Efficacy and safety of decitabine combined with arsenic trioxide in elderly high-risk myelodysplastic neoplasm patients: a retrospective study
Jianzhong Yang
Hematology (2025) Vol. 30, Iss. 1
Open Access
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
Danyang Li, Yigang Yuan, Meng Chen, et al.
Clinical Epigenetics (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Early palliative care in haematological malignancies
Leonardo Potenza, Mario Luppi, Camilla Zimmermann, et al.
BMJ Supportive & Palliative Care (2024) Vol. 14, Iss. 2, pp. 230-232
Open Access | Times Cited: 1
Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome
Muriel R. Battaglia, Joseph Cannova, Rafael Madero‐Marroquin, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 6, pp. 752-768
Closed Access | Times Cited: 1
Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes
Zimin Sun, Liangquan Geng, Erling Chen, et al.
Research Square (Research Square) (2024)
Open Access
Selecting appropriate therapy for lower-risk myelodysplastic syndromes: current state and future prospects
Farzad Teymouri, Constantin A Dasanu
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 15, pp. 1975-1977
Open Access
Page 1

Scroll to top